DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



FMRI of Cholinergic Mechanisms in Schizophrenia

Information source: VA Eastern Colorado Health Care System
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Phase: N/A

Status: Not yet recruiting

Sponsored by: VA Eastern Colorado Health Care System

Summary

This study will examine brain responses during sensory processing in patients with schizophrenia. It will examine the hypothesis that patients treated with clozapine will show decreased responses during sensory processing as compared to patients treated with risperidone.

Clinical Details

Official title: FMRI of Cholinergic Mechanisms in Schizophrenia

Study design: Observational Model: Cohort, Time Perspective: Cross-Sectional

Primary outcome: BOLD FMRI response in hippocampus

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of schizophrenia

- treatment with clozapine or risperidone

Exclusion Criteria:

- Metal in body including pacemaker, aneurism clip, weight over 300 lbs

Locations and Contacts

Dept. of Veterans Affairs Medical Center, Denver, Colorado 80220, United States; Not yet recruiting
JASON TREGELLAS, Ph.D., Phone: 303-315-1086, Email: Jason.Tregellas@uchsc.edu

University of Colorado Denver Medical School, Denver, Colorado 80262, United States; Not yet recruiting
JASON TREGELLAS, Ph.D., Phone: 303-315-1086, Email: Jason.Tregellas@uchsc.edu

Additional Information

Starting date: May 2010
Last updated: July 25, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017